EUVIMEDEUVIMED entdecken
Crossref

A CD44‐Targeted TLR7/8 Nanovaccine for Synergistic Photothermal Immunotherapy

Raju Vivek iD, Namratha Parthasarathy, Babu Rithisa, Karthikeyan Laxmanan iD, Parameswaran Chidambara Rajan

Biotechnology Journal · 2025

DOI: 10.1002/biot.70151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2025. Verfasst von Raju Vivek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Dr. N.G.P Arts and Science College, Coimbatore, Tamil Nadu, India. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Toll-Like Receptor 7, Toll-Like Receptor 8, Photothermal Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, Government of India,.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer continues to remain challenging due to heterogeneity and therapeutic resistance. Conventional therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, often encounter critical limitations such as extensive tissue damage and ineffective elimination of metastatic malignancies. To resolve these issues, nanomaterial‐based therapeutics have progressed to develop improved anticancer treatment outcomes. In this context, a CuS‐R848‐mediated therapeutic nanovaccine (NV) for synergizing photothermal therapy (PTT) with TLR7/8‐driven immunity has been developed. To improve the stability and specificity, the NV was systematically coated with hyaluronic acid (HA) to effectively target and reduce systemic toxicity via CD44‐targeted delivery. Furthermore, the NV under near‐infrared (NIR) light exhibited 98% tumor ablation, including immunogenic cell death (ICD) induction via DAMPs, DC maturation, and significantly enhanced tumor eradication to strengthened immune activation. This dual‐approach combining PTT with ICD demonstrated excellent therapeutic vaccine efficacy in preventing tumor recurrence and metastasis compared to monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronan ReceptorsToll-Like Receptor 7Toll-Like Receptor 8Photothermal TherapyImmunotherapyCancer VaccinesNeoplasmsAnimalsMiceHyaluronic AcidCell Line, TumorHumansNanoparticlesImidazolesFemaleDendritic CellsNanovaccinesMembrane Glycoproteins

Stichwörter der Autor:innen

cancerimmunotherapynanovaccinenear‐infraredphotothermal therapy

Substanzen

Hyaluronan ReceptorsToll-Like Receptor 7Toll-Like Receptor 8Hyaluronic AcidCancer VaccinesImidazolesresiquimodTlr7 protein, mouseNanovaccinesMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Biotechnology, Dr. N.G.P Arts and Science College, Coimbatore, Tamil Nadu, India.
  • Bio-Nano Theranostics Research Laboratory, Cancer Research Program (CRP), School of Life Sciences, Bharathiar University, Coimbatore, Tamil Nadu, India.
  • PG and Research Department of Zoology, Nirmala College for Women, Redfields, Coimbatore, Tamil Nadu, India.
  • Department of Chemistry, Dr. N.G.P Arts and Science College, Coimbatore, Tamil Nadu, India.
  • Major of Biomedical Engineering, Division of Smart Healthcare, College of Information Technology and Convergence, Pukyong National University, Busan, Republic of Korea.

ORCID-Profile: Raju Vivek, Karthikeyan Laxmanan

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, Government of India,

Zitieren

APA

Vivek, R., Parthasarathy, N., Rithisa, B., Laxmanan, K., & Rajan, P. C. (2025). A CD44‐Targeted TLR7/8 Nanovaccine for Synergistic Photothermal Immunotherapy. Biotechnology Journal. https://doi.org/10.1002/biot.70151

Vancouver

Vivek R, Parthasarathy N, Rithisa B, Laxmanan K, Rajan PC. A CD44‐Targeted TLR7/8 Nanovaccine for Synergistic Photothermal Immunotherapy. Biotechnology Journal. 2025. doi:10.1002/biot.70151

BibTeX
@article{Vivek2025,
  author = {Vivek, Raju and Parthasarathy, Namratha and Rithisa, Babu and Laxmanan, Karthikeyan and Rajan, Parameswaran Chidambara},
  title = {A CD44‐Targeted TLR7/8 Nanovaccine for Synergistic Photothermal Immunotherapy},
  journal = {Biotechnology Journal},
  year = {2025},
  doi = {10.1002/biot.70151}
}
Kostenlos starten →